3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Innventure, Inc. received a Nasdaq letter stating its common stock closed below the $1.00 minimum bid price for thirty consecutive business days ended October 22, 2026. The company has until April 21, 2027 to regain compliance, and the letter does not trigger immediate delisting, but there is no assurance the company will regain compliance or secure an additional compliance period.
Nasdaq notice dated October 23, 2026 cites the $1.00 minimum bid price requirement under Listing Rule 5450(a)(1).
Initial Compliance Period runs 180 calendar days, until April 21, 2027, requiring a closing bid of at least $1.00 for ten consecutive business days.
If not regained, the company may receive an additional 180 days by transferring its listing from the Nasdaq Global Market to the Nasdaq Capital Market and meeting other requirements.
The company states it is making diligent efforts to maintain its listing.
22nd Century Group filed a prospectus supplement allowing it to sell up to $18.8 million of common stock under its at-the-market offering with Needham & Company, LLC. During October 2026, the company sold 15,785,757 shares for gross proceeds of about $4.7 million, and it had 19,202,198 shares outstanding as of October 23, 2026, so the sales are large relative to the existing share count and dilute current holders.
Prospectus supplement permits sales of up to $18.8 million of common stock under the Needham & Company, LLC sales agreement, filed October 23, 2026.
During October 2026, the company sold 15,785,757 shares for gross proceeds of about $4.7 million.
19,202,198 shares of common stock were outstanding as of October 23, 2026.
Exhibit 5.1 is an opinion of Foley & Lardner LLP, with a consent filed as Exhibit 23.1.
AMASS Brands said its Chief Financial Officer, Zachary Ament, will resign effective November 16, 2026, and that Geoffrey McFarlane will serve as Interim Chief Financial Officer from November 17, 2026. The filing also reports a revised Series C Preferred Stock certificate that lowers the conversion price floor and a termination of a warrant held by Streeterville Capital, LLC.
CFO Zachary Ament resigned, effective November 16, 2026; the company said the resignation was not due to any disagreement on operations, policies, or financial disclosures.
Geoffrey McFarlane, age 43, was appointed Interim CFO effective November 17, 2026, while the board searches for a permanent CFO.
On October 22, 2026, the Series C Preferred Stock floor price was reduced from $4.00 to $1.00 per share.
The warrant to buy up to 3,500,000 common shares held by Streeterville Capital, LLC was terminated and cancelled, with no payment due from the company.
Traws Pharma entered a Common Stock Purchase Agreement with Roth Principal Investments, allowing the company to sell up to $50,000,000 of newly issued common stock over time at its own discretion. The company is under no obligation to sell any shares, and sales can begin only after a registration statement covering the resale of those shares is declared effective by the SEC.
Total commitment of up to $50,000,000 in newly issued common stock, at the company's option
Purchase price set at 94.0% of volume weighted average price, a fixed 6.0% discount, for market open, intraday, pre-market and post-market purchases
Sales require the closing price to be at least $0.10 (Threshold Price) and an effective registration statement; the period runs 36 months from the Commencement Date
Agreement dated October 23, 2026, with a related Registration Rights Agreement
Medicus Pharma Ltd. said Nasdaq notified it on October 23, 2026 that it had regained compliance with the $1.00 minimum bid price requirement and that the matter is closed. The notice supersedes an October 20, 2026 delisting determination letter that would have removed the company's shares and warrants from The Nasdaq Capital Market. The company states there can be no assurance it will maintain compliance in the future.
Nasdaq notified the company on October 23, 2026 that it regained compliance with the $1.00 minimum bid price requirement.
The closing bid price was at or above $1.00 for ten consecutive business days, from October 12 to October 23, 2026.
An October 20, 2026 delisting determination letter was superseded and rendered moot by the compliance notice.
Earlier, Nasdaq had found the company ineligible for a second 180-day compliance period because it does not meet the minimum $5 million stockholders' equity requirement.
Expion Energy amended and restated its August 2026 private placement, under which it sold $9,000,000 of 8% convertible debentures and warrants. The debentures will now convert directly into common stock at $4.25 rather than into preferred stock that required stockholder approval, and the additional investment right is now a $91,000,000 debenture purchase option instead of preferred stock. The change affects potential dilution for shareholders, and the lead purchaser is linked to the company's former chief executive and chairman.
Original August 21, 2026 deal: $9,000,000 of 8% convertible debentures and warrants for up to 2,117,219 common shares
Amended October 22, 2026: debentures convert into common stock at an initial price of $4.25, subject to adjustment
Floor conversion price set at $0.72 per share; purchasers may buy up to $91,000,000 of additional convertible debentures within 18 months
Lead purchaser Five Narrow Lane, LP is linked to former CEO and Chairman Joseph Hammer; the deal was approved by disinterested directors
Transocean and Valaris filed a joint proxy statement on October 14, 2026 for shareholder votes on the planned Business Combination, under which Transocean would acquire all Valaris shares for 15.235 Transocean shares per Valaris share. Both shareholder meetings are scheduled for November 24, 2026, with a Bermuda court sanction hearing on November 26, and the companies expect the deal to close on or about December 1, 2026, if approvals are obtained.
Transocean and Valaris shareholder meetings are both scheduled for November 24, 2026.
Exchange ratio: 15.235 Transocean shares for each Valaris share.
Bermuda Supreme Court sanction hearing scheduled for Thursday, November 26, 2026.
Transocean expects the Business Combination to close on or about December 1, 2026, if conditions are met.
Valaris and Transocean filed a joint proxy statement on October 14, 2026 for the planned Transocean acquisition of Valaris, under which each Valaris share would be exchanged for 15.235 Transocean shares. Valaris and Transocean shareholder meetings are scheduled for November 24, 2026, and a Bermuda court sanction hearing is set for November 26, 2026, with completion anticipated on or about December 1, 2026. The filing gives no financial results, and completion still depends on shareholder and court approvals and other conditions.
Exchange ratio: 15.235 Transocean shares for each Valaris share under a Bermuda scheme of arrangement
Valaris Court Meeting and Transocean Meeting both scheduled for November 24, 2026
Bermuda Supreme Court sanction hearing scheduled for November 26, 2026; closing anticipated on or about December 1, 2026
Circle8 Group disclosed that its Lyneer subsidiary received a default notice from its professional employer organization, Employers Personnel, LLC, alleging missed payments under a service agreement. Separately, lender SPP Credit Advisors issued default notices under a financing agreement and a bridge loan, and senior lender SLR said it intends to sell substantially all Lyneer assets on or after October 27, 2026. The company disputes the validity of the asset sale notice and is reviewing the defaults, which could materially affect shareholders given the threatened asset sale.
PEO Employers Personnel, LLC alleged Lyneer is in default of payment obligations under its service agreement; discussions are ongoing.
SPP Credit Advisors letter dated October 14, 2026 asserted events of default under the Financing Agreement dated April 29, 2025 and the Bridge Loan Agreement dated June 18, 2024.
On October 15, 2026, Lyneer received notice that SLR intends to sell substantially all Lyneer assets under Article 9 of the UCC on or after October 27, 2026.
The company disputes the validity of the SLR notice and says it is reviewing the purported defaults in light of a Settlement Agreement dated August 7, 2026.
ARC Group Securities Acquisition I received a Nasdaq notice on October 20, 2026, saying its outstanding warrants no longer meet the $1 million minimum aggregate market value requirement. The notice is a deficiency warning, not an imminent delisting, and it has no current effect on trading of the warrants; the company plans to submit a compliance plan.
Nasdaq notice dated October 20, 2026; warrants fell below the $1 million aggregate market value minimum under Listing Rule 5452(b)(C)
Compliance plan due to Nasdaq by December 4, 2026
If the plan is accepted, Nasdaq may extend the compliance period to April 18, 2027
Notice affects only the warrants, not other securities, and does not currently affect their listing or trading
Ardent Health said its Board found on October 19, 2026 that former CEO Martin J. Bonick failed to fully disclose third-party compensation, and recharacterized his June 2026 separation as a termination for Cause. The company will stop about $4.5 million of unpaid severance and cancel his unvested performance-based restricted stock units, and it reserved its rights to pursue other remedies. The filing says no financial statements or previously disclosed results need revision.
Bonick's employment as President and CEO and his board service ended effective June 2, 2026.
On October 19, 2026, the Board determined that facts discovered after the separation date would have supported a termination for Cause.
Ardent will discontinue about $4.5 million of unpaid cash severance and cancel or forfeit outstanding unvested PRSUs.
The company says none of its financial statements or previously disclosed results need to be revised or corrected.
Dragonfly Energy Holdings received a Nasdaq extension, granted October 22, 2026, to regain compliance with the minimum stockholders' equity requirement, which its June 30, 2026 10-Q showed as a $(184,000) deficit against a $2.5 million minimum. The company must file a public report evidencing compliance by December 31, 2026, and failing that could face delisting, with a right to appeal to a Nasdaq hearings panel.
Stockholders' equity deficit of $(184,000) as of June 30, 2026, versus a $2.5 million minimum
Company submitted a compliance plan to Nasdaq staff on October 5, 2026
Nasdaq extension runs through December 31, 2026; compliance report is due on or before that date
If compliance is not evidenced, staff will issue written notice of delisting and the company may appeal
The Trustee, Argent Trust Company, said SoftVest and other holders of more than 15% of the units requested a special meeting of unitholders on November 23, 2026. The proposals include approving an amendment to the Trust Indenture to effect a Business Combination under a Combination Agreement, approving the PBT Land and Minerals, Inc. Omnibus Incentive Plan, and authorizing a possible adjournment. The vote would decide whether the proposed transaction proceeds, which would affect unitholders' holdings.
Special meeting requested for November 23, 2026, with a record date of October 13, 2026.
Proposals cover a Trust Indenture amendment to effect the Business Combination, the Omnibus Incentive Plan, and a possible adjournment.
Trustee intends to call the meeting under the Indenture; notice to be mailed beginning October 23, 2026.
Trustee is not a party to the Combination Agreement and is not making a voting recommendation.
Evernorth Holdings entered an agreement on October 23, 2026, that lets it sell up to 5,218,935 newly issued Class A common shares to CF Principal Investments LLC (Cantor) over time, at its option. The company must pay a commitment fee of $521,893.50, and sales would be priced at 97% of the volume weighted average price, which can add dilution for existing shareholders.
Up to 5,218,935 new Class A common shares may be sold to Cantor at the company's discretion
Purchase price is 97% of the volume weighted average price during the purchase period, subject to a $1.00 minimum threshold price
Upfront commitment fee of $521,893.50, with any true-up capped so total fees do not exceed $1,000,000
Company must file an initial resale registration statement on Form S-1 within 30 days of the registration rights agreement
Unusual Machines completed its merger with DroneNX LLC (Upgrade Energy) on October 19, 2026, adding U.S. drone battery manufacturing to its product line. The company issued 1,792,012 common shares valued at about $25.0 million and paid $1,000,000 in cash, with up to $26,000,000 more in earn-out payments possible; the filing does not give revenue or profit figures for the business.
Closing date: October 19, 2026; consideration of 1,792,012 shares (about $25.0 million) plus $1,000,000 cash
Earn-out of up to $26,000,000 cash, for aggregate merger consideration of up to $52,000,000
Matthew Barnard became CEO of Upgrade Energy; employment agreement has a two-year initial term and registration rights cover the issued shares
Separately, on October 20, 2026, 137,260 shares were issued to Rotor Lab sellers as earn-out consideration
Freshpet's board committee approved an enhanced compensation package for Nicola Baty, who became President effective October 21, 2026, while continuing as Chief Operating Officer. The package includes a $675,000 base salary, a long-term incentive target of at least 250% of base salary, and restricted stock units covering 58,245 shares that vest in full on June 30, 2029.
Base salary of $675,000 and annual cash bonus target of at least 80% of base salary
Long-term equity incentive target of at least 250% of base salary
RSUs for 58,245 shares under the 2024 Equity Incentive Plan, vesting in full on June 30, 2029, subject to continued employment
Melar Acquisition Corp. I shareholders approved the business combination with Everli Global Inc. and related proposals at an extraordinary general meeting on October 22, 2026, with no votes against any proposal reported as zero abstentions. Holders of 3,852,564 Class A shares redeemed for a pro rata share of the trust account, leaving approximately $0.8 million in the trust after redemptions, and Melar expects the combination to close promptly once remaining conditions are met.
Business Combination Proposal: 9,425,113 votes for and 23,978 against, with 0 abstentions
Redemptions: 3,852,564 Melar Class A Ordinary Shares redeemed; approximately $0.8 million remains in the trust account
Combined company to operate as Everli Global Holdings Inc. and trade on Nasdaq as EVRL and EVRLW once the deal closes
Sunrise Realty Trust stockholders voted at a special meeting on October 23, 2026 to approve issuing about 8,464,955 shares of common stock under the merger agreement with Southern Realty Trust Inc. The company also declared a $0.09 per share prorated Stub Period Dividend, and the merger is expected to close on or around November 5, 2026, subject to customary closing conditions.
Stock Issuance Proposal approved: 7,365,863 for, 640,115 against, 35,579 abstain
Turnout was about 59.5% of the 13,515,851 shares outstanding on the September 10, 2026 record date
Stub Period Dividend of $0.09 per share payable November 5, 2026 to holders of record on November 2, 2026
Merger expected to close on or around November 5, 2026; SRT stockholders also approved the merger on October 23, 2026
Stem, Inc. received a non-compliance letter from the New York Stock Exchange on October 20, 2026, confirming it does not meet the NYSE requirement for average market capitalization and stockholders' equity of at least $50 million each. The company plans to submit a business plan to regain compliance within 18 months, and its common stock will continue trading on the NYSE during the cure period if the plan is accepted.
NYSE non-compliance letter received October 20, 2026; company notified NYSE October 19, 2026
Standard requires average market capitalization of at least $50 million over 30 trading days and stockholders' equity of at least $50 million
Business plan due within 45 days of receipt of the letter, with a target of regaining compliance within 18 months
Stock remains listed on the NYSE during the cure period, subject to NYSE acceptance of the plan and quarterly monitoring
Akebia Therapeutics received a Nasdaq deficiency letter on October 21, 2026, because its common stock closed below $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing, and the company has until April 19, 2027 to regain compliance, but it may face delisting if it does not.
Nasdaq notice received October 21, 2026 for closing bid price below $1.00 over 30 consecutive business days
Initial compliance period runs 180 calendar days, until April 19, 2027
Regaining compliance requires at least $1.00 closing bid for 10 consecutive business days; a second 180-day period may be possible
Company says it may consider a reverse stock split, but cannot assure it will regain compliance
Polar Power, Inc. reported that it believes it has regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement, based on a series of convertible note, preferred stock, warrant and equity line transactions. The company estimates pro forma stockholders' equity of approximately $2.9 million, but the figures are preliminary and unaudited, and Nasdaq will keep monitoring compliance, so the company may still face delisting if it does not show compliance at its next periodic report.
Nasdaq deficiency letter dated May 1, 2026 cited the $2,500,000 minimum stockholders' equity rule; extension granted June 29, 2026
Company estimates preliminary pro forma stockholders' equity of approximately $2.9 million as of the filing date
Nasdaq will monitor compliance; the company may be subject to delisting if it does not evidence compliance at its next periodic report
Compliance must be demonstrated in a public report on or before October 28, 2026
Red Cat Holdings signed a Business Combination Agreement dated October 21, 2026, with Steyr Motors AG, supporting a voluntary public cash tender offer by its Austrian subsidiary to acquire all 5,251,261 Steyr Motors shares at EUR 39.00 each. The largest Steyr Motors shareholder, B&C Holding Österreich GmbH, has agreed irrevocably to tender its shares, and Steyr Motors' boards support the offer. The deal remains subject to foreign investment approvals and a minimum acceptance threshold, and the acceptance period ends December 18, 2026 unless extended.
Offer price is EUR 39.00 in cash per Steyr Motors share, for all 5,251,261 shares.
Acceptance period ends December 18, 2026, at 5:00 p.m. CET, extendable by the Bidder up to 16 weeks.
Conditions include foreign direct investment approvals in Austria, Australia, Italy and the UK by June 30, 2027, and a minimum acceptance of 50% plus one share.
Steyr Motors may terminate if the Offer Document is not published by November 15, 2026, unless the delay is caused by Steyr Motors.
Reliance Global Group signed a non-binding letter of intent on September 23, 2026 to acquire the assets of a privately held GPU cloud and marketplace business for up to $3,750,000 in cash. The company says the deal would mark its entry into AI infrastructure and would be funded without issuing shares, but the letter is non-binding and closing is anticipated in early November 2026, subject to definitive agreements. The filing also reports cash compensation settlements for the CEO, COO and a vice president in place of unissued stock awards.
Up to $3,750,000 in cash: $3,000,000 at closing, $375,000 escrow tied to revenue threshold, $375,000 payable 12 months after closing
Company plans to adopt GPU Exchange DBA name and change Nasdaq symbol from EZRA to XGPU; effective date to be announced separately
On October 19, 2026, committee approved cash in lieu of stock: $440,000.00 to Ezra Beyman (partial), $224,193.84 to Judah Korman and $124,730.13 to Mordy Beyman
Filing lists related-party payments; Korman and Mordy Beyman are relatives of a director and the CEO respectively
Offerpad said Chief Financial Officer Peter Knag will step down effective October 20, 2026, and will stay on as a Senior Advisor through November 30, 2026 to support an orderly transition. Andrew Pieper, the company's Senior Vice President and Controller, was appointed Interim Chief Financial Officer and principal financial and accounting officer. The filing says Knag's departure was not due to any disagreement with the company, and the filing does not discuss financial results.
Peter Knag stepped down as Chief Financial Officer effective October 20, 2026.
Knag remains employed as a Senior Advisor through November 30, 2026.
Andrew Pieper, 44, was appointed Interim Chief Financial Officer effective October 20, 2026.
Knag is eligible for separation payments and benefits under his employment agreement.
Zevia agreed on October 22, 2026 to sell up to $20 million of Series A Senior Convertible Preferred Stock to Bubble Holdings, an affiliate of GP Investments; $15 million closed that day and the remaining $5 million depends on 2026 net sales and Adjusted EBITDA targets. The company also said preliminary third quarter 2026 net sales are about $48 million, above its prior $44 million to $46 million guidance, and Adjusted EBITDA is expected to be between negative $900 thousand and negative $1.0 million, better than its prior negative $3.0 million to negative $3.5 million range, though the convertible preferred is dilutive to common shareholders.
$15 million of Series A Preferred Stock issued October 22, 2026; remaining $5 million deferred closing requires 2026 net sales of at least $172.5 million and Adjusted EBITDA of no less than negative $3.0 million
Preferred accrues a 6.00% dividend and converts initially at $1.448 per share, with conversion capped at 14,428,844 shares
Purchaser gets the right to designate one board director; board size increased to eight members
Preliminary Q3 2026 net sales about $48 million vs. prior guidance of $44 million to $46 million; full results due November 4, 2026
T3 Defense Inc. said it believes it has regained compliance with Nasdaq's $10 million minimum stockholders' equity requirement, after holders exercised about 96% of its outstanding warrants as of September 30, 2026. The company has asked Nasdaq to confirm the resolution, but Nasdaq has not done so, and the company may face delisting if its next periodic report does not show compliance.
Nasdaq notice dated August 20, 2026 cited the $10,000,000 minimum stockholders' equity requirement under Listing Rule 5450(b)(1)(A).
Warrant liability rose from about $24.5 million at December 31, 2025 to about $124.4 million at June 30, 2026, producing a stockholders' deficit of about $19.7 million at that date.
As of September 30, 2026, warrant holders had exercised about 96% of outstanding warrants; pro forma stockholders' equity was about $99.9 million.
Nasdaq has not confirmed compliance; the next test is the Form 10-Q for the quarter ending September 30, 2026.
Kloeckner & Co shareholders did not approve the proposed domination and profit and loss transfer agreement (DPLTA) with Worthington Steel GmbH at an extraordinary general meeting in Düsseldorf, so the DPLTA will not become effective. Worthington says it will operate within the existing ownership and governance structure, while the vote's outcome does not affect Kloeckner's consolidation into its financial reporting or its financing arrangements.
Kloeckner shareholders did not give the required approval for the DPLTA at the extraordinary general meeting, and the agreement will not become effective.
Worthington Steel holds approximately 62% of Kloeckner's share capital and voting rights following the takeover offer and delisting tender offer.
Kloeckner's results have been consolidated since the June 2026 acquisition of a majority stake, and the vote does not change this consolidation.
CEO Geoff Gilmore said the vote will affect the timing, mix and manner in which certain goals can be realized, particularly in the near term.
Bolt Biotherapeutics acquired Prana Therapies through a stock-for-stock reverse merger and, concurrently, agreed to a $120 million upfront private placement of Series D preferred stock. After the financing, pre-transaction Bolt holders are expected to own about 6.9% of common stock, Prana holders about 51.7%, and private placement investors about 41.4%, so existing Bolt shareholders face substantial dilution and a major change in ownership.
Bolt issued 430,746 shares of common stock and 16,360.929 shares of Series D preferred stock to Prana stockholders; each preferred share converts into 1,000 common shares.
The private placement covers 13,995.311 Series D preferred shares for $120 million in upfront gross proceeds, with warrants for up to an additional $60 million upon exercise.
Conversion of the Series D preferred stock requires Bolt stockholder approval, and the private placement is expected to close on October 26, 2026.
The company expects the financing to fund operations into 2028; lead program PRA-216 has Phase 2 patient data expected from the second quarter through the fourth quarter of 2027.
Arcosa, Inc. completed its merger, and each outstanding common share was converted into the right to receive $150.00 in cash, without interest. The company became a wholly-owned subsidiary of Parent, its directors and officers resigned, and its common stock is being removed from listing on the NYSE and NYSE Texas, so public shareholders no longer hold shares in the company.
Merger Consideration of $150.00 per share in cash, less applicable withholding taxes
Aggregate cash consideration for common stock and cash-settled equity awards was approximately $7.5 billion
Trading on the NYSE and NYSE Texas was halted before the open on October 23, 2026, with delisting requested
Credit Agreement terminated after repayment of approximately $450.1 million in principal, accrued interest and other amounts
Tempus AI announced agreements with Bristol-Myers Squibb and Pathos AI to expand use of its de-identified real-world data, software and models, with aggregate cash payments to Tempus of $192.5 million over about five years. The Pathos neurology deal is a related-party transaction, reviewed and approved by a special committee of disinterested directors, which shareholders may weigh when assessing the agreements.
BMS oncology Statement of Work runs through December 31, 2031, with $137.5 million in fixed payments invoiced quarterly.
Pathos Neuro Order Form provides up to $55 million, including $100 per delivered record and $5.0 million for record updates; the total depends on records delivered.
Pathos is a related party because of overlapping executive leadership and equity ownership, so a special committee of disinterested directors approved the neurology deal.
CRH announced on October 23, 2026 that it has completed its acquisition of Arcosa, Inc., a U.S. aggregates and critical infrastructure provider, for a total enterprise value of approximately $8.5 billion. The company said it will provide updated full-year 2026 guidance reflecting the deal with its third-quarter results on October 29.
Total enterprise value of approximately $8.5 billion, as stated in the press release.
Agreement to acquire Arcosa was first announced on June 22, 2026.
CRH will issue updated full-year 2026 guidance reflecting the acquisition with third-quarter results on October 29.
The filing furnishes the press release as Exhibit 99.1 under Item 7.01 and does not include new financial results.
UWM Holdings Corporation released preliminary, unaudited third-quarter 2026 results and said total revenue for 2026 will be approximately $3.35 billion to $3.50 billion, lower than it expected earlier in the year because of lower industry-wide origination volume. The company also reiterated a $400 million rights offering, backstopped by Oaktree and SFS Group, an entity controlled by CEO Mat Ishbia, which the filing says could dilute existing shareholders.
Preliminary Q3 2026: loan origination volume of $33.4 billion, total revenue of $800 million to $825 million, net income of $205 million to $220 million, and adjusted EBITDA of $170 million to $190 million
Full-year 2026 total revenue now expected at $3.35 billion to $3.50 billion, lower than earlier expectations
Rights offering of up to $400 million began October 5, 2026; subscription price is the greater of $2.00 and 85% of the 10-day VWAP; the filing says material subscription from outside investors is unlikely
Oaktree and SFS Group (controlled by Mat Ishbia) have agreed to backstop any shortfall so gross proceeds are at least $400 million
Aardvark Therapeutics reported exploratory efficacy and safety data from its previously terminated Phase 3 HERO trial and open-label extension, which the company says are directionally consistent with continued development of ARD-101 for Prader-Willi syndrome. The company states the partial data are not sufficient to draw definitive conclusions, the HERO trial was stopped early, and the FDA has lifted the clinical hold, so the company plans to request an FDA meeting on a new Phase 3 design.
HERO trial was terminated early with 67 of 90 planned participants randomized; all efficacy data are considered exploratory
OLE participants who switched from placebo to ARD-101 had an observed average 6-point reduction in HQ-CT score
One Grade 4 cardiac serious adverse event occurred at 800 mg twice daily with pitolisant, which the FDA concurred is related to a drug-drug interaction
FDA lifted the clinical hold on October 22, 2026; the company expects to resume PWS clinical activities in 2027
LKQ preliminarily reported third-quarter 2026 revenue of $3.32 billion, down from $3.50 billion a year earlier, and a net loss of $16 million to $32 million, compared with net income of $178 million in the third quarter of 2025. The company cited underperformance in Europe, withdrew its full-year 2026 guidance, and replaced CEO Justin Jude with Salvatore A. Abbate, effective December 15, 2026, with an interim Office of the CEO in place until then.
Preliminary Q3 2026 revenue was $3.32 billion versus $3.50 billion in Q3 2025; parts and services organic revenue declined 5.4%.
Diluted loss per share of $0.06 to $0.12 compares with diluted EPS of $0.69 a year earlier; adjusted diluted EPS was $0.47 to $0.53 versus $0.84.
Europe parts and services organic revenue declined 9.8%, and Europe segment EBITDA margin was 4.1% to 5.1%, versus 10.0% a year earlier.
Full-year 2026 guidance, last updated July 30, 2026, is withdrawn; Andy Hamilton left LKQ Europe and Alvarez & Marsal was retained to advise on European operations.
ORIC Pharmaceuticals presented updated Phase 1b data for its enozertinib (ORIC-114) program at ESMO Congress 2026 on October 23, 2026, reporting an 84% investigator-assessed systemic response rate and a 70% investigator-assessed intracranial response rate in 26 patients with EGFR atypical NSCLC. The company plans to start a global Phase 3 trial, Redwood-1, in the first half of 2027. The filing contains clinical data only and no financial results, so the update's effect on shareholders depends on future trial outcomes and funding.
Investigator-assessed systemic ORR was 84% (21 of 25); BICR-assessed systemic ORR was 80% (20 of 25) as of the September 4, 2026 cutoff
BICR RANO-BM intracranial ORR was 67% (10 of 15), with a 40% (6 of 15) complete response rate
Six patients (23%) had Grade 3 treatment-related adverse events, all resolved with dose modifications; no Grade 4 or 5 events were reported
Redwood-1 Phase 3 trial plans to enroll approximately 360 patients, with initiation planned for the first half of 2027
Gentex reported third-quarter 2026 net sales of $647.7 million, down from $655.2 million a year earlier, with GAAP diluted EPS of $0.43 versus $0.46. The company also lowered its 2026 gross margin guidance to 34.0% to 34.5% from 34.5% to 35.5%, citing higher precious metal costs and lower-than-expected sales, which matters to shareholders because it signals weaker profitability for the year.
Q3 2026 net income attributable to Gentex was $90.6 million, compared with $101.0 million in Q3 2025
Q3 gross margin was 33.4%, compared with 34.4% a year earlier
2026 gross margin guidance was cut to 34.0% to 34.5%; full-year revenue outlook of approximately $2.65 billion was kept at the low end of the prior range
The company repurchased 5.7 million shares for $132.6 million in the quarter and has about 24.3 million shares left under its plan
American Express reported third-quarter 2026 net income of $3.7 billion, up from $2.9 billion a year earlier, and diluted EPS of $5.42, up 31%. Excluding a $982 million pre-tax gain from the sale of its GBTG stake and a $336 million pre-tax restructuring charge, adjusted EPS was $4.68, up 13%. The company raised its full-year 2026 EPS guidance to $18.30 to $18.60 ($17.60 to $17.90 adjusted), which signals higher expected earnings for shareholders.
Total revenues net of interest expense were $20.1 billion, up 9% year over year, with billed business up 8% to $454.0 billion in the quarter.
Diluted EPS was $5.42 versus $4.14 a year ago; adjusted EPS was $4.68 versus $4.14.
Full-year 2026 EPS guidance was raised to $18.30 to $18.60, or $17.60 to $17.90 adjusted.
Provisions for credit losses fell to $1.0 billion from $1.3 billion, and the net write-off rate was 1.8% versus 1.9% a year ago.
Booz Allen Hamilton reported fiscal second-quarter 2027 results for the period ended September 30, 2026, with revenue of $2.8 billion, down 3.9% year over year, while net income rose 3.4% to $181 million. The company raised its fiscal 2027 Adjusted Diluted EPS guidance to $6.50 to $6.70 from $6.00 to $6.35, but revenue guidance midpoint was unchanged and the revenue growth range was narrowed.
Q2 revenue of $2.8 billion, down 3.9%; net income of $181 million, up 3.4%
Adjusted Diluted EPS of $1.76, up 18.1%; GAAP diluted EPS of $1.50, up 5.6%
Fiscal 2027 Adjusted Diluted EPS guidance raised to $6.50 to $6.70 from $6.00 to $6.35
Fiscal 2027 revenue guidance of $11.3 billion to $11.6 billion, versus $11.2 billion to $11.7 billion previously
Tango Therapeutics reported updated Phase 1/2 data for vopimetostat combined with Revolution Medicines' RAS(ON) inhibitors, with an 82% objective response rate in 22 efficacy-evaluable pancreatic cancer patients as of an August 20, 2026 data cutoff. The company also approved a strategic reprioritization on October 22, 2026, which includes reducing its workforce by approximately 14%, mostly in research, and deprioritizing novel target discovery. For shareholders, the data support a planned Phase 3 study, while the restructuring and the dose level 2 safety results add uncertainty.
Pancreatic cohort: 82% objective response rate (18 of 22), median PFS not yet reached, 9-month PFS rate of 88%, as of August 20, 2026
Dose level 2 (250 mg vopimetostat) was not well tolerated, with 3 dose-limiting toxicities in 2 of 4 safety-evaluable patients
Planned global randomized Phase 3 in front-line MTAP-deleted pancreatic cancer expected to start in the first half of 2027; NSCLC monotherapy data now expected in January 2027
Board approved reprioritization on October 22, 2026; approximately 14% workforce reduction, mostly in the research group
First Citizens BancShares reported third-quarter 2026 net income of $606 million, down from $672 million in the second quarter, and earnings per common share of $51.23 versus $55.52. The Board also authorized a share repurchase program of up to $1.2 billion of Class A common stock during 2027, though the company is not obligated to buy any minimum amount.
Net income available to common stockholders was $577 million, or $51.23 per share, down $63 million from $640 million, or $55.52 per share, in the second quarter.
Adjusted earnings per common share were $55.37, compared with $57.09 in the second quarter.
Net interest income rose $43 million to $1.70 billion, while noninterest income fell $42 million to $734 million.
The new 2027 repurchase plan authorizes up to $1.2 billion; the company repurchased $600 million of Class A shares in the third quarter.
FTAI Infrastructure's Jefferson Terminal unit announced plans for a private offering of up to $270 million of notes, a preliminary amount subject to market conditions, to finance its acquisition of DRUbit LLC for an enterprise value of $255 million and pay related fees. Jefferson reported a net loss of approximately $52.2 million for the six months ended June 30, 2026, and expects the acquisition to more than double its annual Adjusted EBITDA to about $100 million, though the filing gives no assurance the financing will be completed.
Notes offering of up to $270 million, preliminary and subject to change, to be offered to qualified institutional buyers and non-U.S. persons
Acquisition of DRUbit LLC from an affiliate of US Development Group LLC at an enterprise value of $255 million, announced in a September 28, 2026 8-K
Jefferson reported a six-month net loss of approximately $52.2 million and Adjusted EBITDA of approximately $19.2 million
Jefferson targets 2027 Adjusted EBITDA of approximately $138 million and total debt of approximately $1,214 million on a pro forma basis
MarketAxess reported third-quarter 2026 revenue of $210.4 million, up 1% from a year earlier, while diluted EPS fell to $1.53 from $1.84 as expenses rose 10% and included $13.1 million of merger-related costs. The company withdrew its 2026 annual guidance and medium-term targets, and it declared a $0.78 quarterly dividend, both tied to its pending merger with Intercontinental Exchange, under which shareholders would receive $167.00 in cash per share.
Q3 2026 revenue $210.4 million, up 1%; net income $54.0 million, down 21%; diluted EPS $1.53 vs. $1.84 a year earlier
EPS excluding notable items was $1.86, up 1% from $1.84; operating margin was 35.4%, down 560 basis points
2026 annual guidance and medium-term financial targets withdrawn; earnings conference calls and monthly volume releases suspended
Merger with ICE at $167.00 cash per share; DOJ and FTC granted early termination of the HSR waiting period on October 21, 2026; stockholder approval and other conditions remain
Autoliv reported third-quarter 2026 net sales of $2,693 million, down 0.5%, and diluted EPS of $2.13, down 6.8%. It narrowed its full-year 2026 adjusted operating margin guidance to around 10.5%, the low end of its prior range of around 10.5-11%, citing higher raw material, logistics and Thailand flooding costs, while organic sales and operating cash flow expectations were unchanged. In the quarter, the company paid $63 million in dividends and repurchased shares for $150 million.
Q3 2026 net sales were $2,693 million, down 0.5%; organic sales fell 1.1% versus a 1.9% decline in global light vehicle production.
Diluted EPS was $2.13, down 6.8%; adjusted diluted EPS was $2.19, down 5.7%.
Full-year 2026 adjusted operating margin guidance narrowed to around 10.5%, the low end of the around 10.5-11% range; organic sales growth of around 0% and operating cash flow of around $1.2 billion were unchanged.
Q3 dividends totaled $63 million ($0.87 per share) and 1.23 million shares were repurchased for $150 million.
Zymeworks signed a Collaboration and License Agreement with Roche on October 22, 2026, giving Roche exclusive worldwide rights to develop and commercialize its ZW209 DLL3-targeting trispecific T-cell engager. The deal includes a $55 million upfront payment and up to $718 million in milestones, and it takes effect only after U.S. Hart-Scott-Rodino clearance, while Roche can terminate at any time.
Upfront non-refundable payment of $55 million, due after HSR Clearance
Non-refundable $40 million milestone on initiation of the Phase Ib Trial, plus up to $718 million in other milestones
Tiered high-single-digit to mid-teen royalties on annual net sales, with Zymeworks conducting the Phase Ia trial at Roche's expense
Roche may terminate the agreement in its sole discretion at any time; Zymeworks' exclusivity restriction runs up to five years
Zai Lab agreed on October 22, 2026 to sell 11,340,000 American depositary shares to accredited investors at $22.04 per ADS in a private placement. The company expects about $250 million in proceeds before placement fees and other expenses, which it plans to use to fund pipeline development and for working capital and general corporate purposes. The new shares will add to the share count, and the company must file a resale registration statement within 15 days of closing.
Sale of 11,340,000 ADSs at $22.04 per ADS to accredited investors, announced October 22, 2026
Expected gross proceeds of about $250 million before placement agent fees and other expenses
Closing expected on or about October 27, 2026, subject to customary closing conditions
Company must file a resale registration statement within 15 days of the closing, subject to allowable delays
S&P Global furnished unaudited pro forma financial statements showing its results as if the July 1, 2026 spin-off of its Mobility segment into Mobility Global Inc. had occurred earlier. For 2025, pro forma diluted EPS from continuing operations is $13.74, compared with $14.66 as reported, and pro forma revenue is $13,589 million, compared with $15,336 million historically. Shareholders should note that these figures are illustrative and not indicative of future results.
Spin-off completed July 1, 2026; holders of record on June 15, 2026 received one Mobility Global share for each S&P Global share held
Pro forma 2025 revenue of $13,589 million versus $15,336 million historically; pro forma 2025 diluted EPS of $13.74 versus $14.66
Pro forma six months ended June 30, 2026 revenue of $7,397 million and diluted EPS of $8.56 versus $8.81 historically
Filing cites $53 million of additional non-recurring separation costs, classified within discontinued operations
Flagstar Bank reported third quarter 2026 net income attributable to common stockholders of $3 million, or $0.01 per diluted share, down from $26 million, or $0.06, in the second quarter but up from a $45 million loss in the third quarter of 2025. The quarter included a $22 million income tax benefit from a federal tax audit settlement, while the provision for credit losses rose $58 million to $76 million, and management said full achievement of its long-term strategic objectives has shifted to 2028 from 2027.
Total revenues rose 3% to $530 million from $516 million in the second quarter, and net interest income rose 5% to $460 million
Provision for credit losses increased $58 million to $76 million, mainly reflecting net charge-offs of $74 million
A $22 million income tax benefit from the settlement of a 2019-2021 federal tax audit helped results
Management moved the full realization of its long-term strategic objectives to 2028 from 2027, citing a higher-for-longer interest rate environment
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.